Trial alert from the PACIFIC study: Robust and sustained survival benefit with consolidation durvalumab after concurrent chemoradiotherapy for unresectable, stage III non-small-cell lung cancer

 Recently released results on survival analyses from the PACIFIC study focusing on the benefits of durvalumab in patients with unresectable, stage iii non-small-cell lung cancer (NSCLC) and no cancer progression following concurrent chemoradiotherapy treatment indicated that "42.9% of patients randomly assigned to durvalumab remain alive at 5 years and 33.1^ of patients remain alive and free of disease progression. 

Click here to read more about this study, the first to "demonstrate a survival advantage with immune checkpoint inhibitor in a curative-intent setting."

Source mentioned: Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. JCO; Published online 2 February 2022. DOI: 10.1200/JCO.21.01308